Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:52 AM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:47 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a direct, material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:42 AM UTC

Segments 12-16 report that Moderna's personalized cancer treatment succeeded in a Phase 3 trial, showing longer recurrence-free survival when combined with Keytruda, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:37 AM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer returning or spreading. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:32 AM UTC

Segments 13-16 report positive Phase 3 results for Moderna's personalized cancer vaccine, showing improved recurrence-free survival and a 177% stock surge, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:27 AM UTC

Segments 12-15 report that Moderna's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the treatment plus Keytruda going longer without cancer recurrence, and Moderna shares closing 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:22 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a material positive catalyst, and shares surged 177%.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:22 AM UTC

Segments 12-16 report that Moderna's personalized cancer treatment succeeded in a Phase 3 trial, with patients going longer without cancer recurrence, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:20 AM UTC

Segments 13-16 report that Moderna's personalized cancer treatment succeeded in a Phase 3 trial, with patients going longer without cancer recurrence, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:02 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine in combination with Keytruda, showing longer recurrence-free survival compared to Keytruda alone. The stock surged 177% on the news, indicating a material positive catalyst and improved expected fundamentals.